Duality Biotherapeutics, Inc.
映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 9606)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026

References are made to the notice of extraordinary general meeting (the "**Notice**") and the circular (the "**Circular**") of Duality Biotherapeutics, Inc. (the "**Company**") both dated April 14, 2026. Unless otherwise indicated, capitalized terms used herein have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of the resolutions proposed at the EGM were as follows.

ORDINARY RESOLUTIONS		**Number of votes cast and approximate percentage of total number of votes cast**	
		For	**Against**
1.	To consider and approve the RMB Share Issue and the Specific Mandate (including but not limited to the particulars as set out in the section headed "Proposed RMB Share Issue" in the Circular).	46,784,003 (99.320188%)	320,220 (0.679812%)
2.	To consider and approve the authorization to the Board and its authorized person to exercise full powers to deal with matters relating to the RMB Share Issue (including but not limited to the particulars as set out in the section headed "Resolution on authorization to the Board and its authorized person to exercise full powers to deal with matters relating to the RMB Share Issue" in the Circular).	46,765,455 (99.280812%)	338,768 (0.719188%)
3.	To consider and approve the plan for undertaking accumulated unrecovered losses prior to the RMB Share Issue (including but not limited to the particulars as set out in the section headed "Plan for undertaking accumulated unrecovered losses prior to the RMB Share Issue" in the Circular).	46,784,003 (99.320188%)	320,220 (0.679812%)

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
4.	To consider and approve the plan for stabilization of the price of the RMB Shares for the three years after the RMB Share Issue in the form as set forth in Appendix I to the Circular.	46,784,003 (99.320188%)	320,220 (0.679812%)
5.	To consider and approve the dividend return plan for the three years after the RMB Share Issue in the form as set forth in Appendix II to the Circular.	47,045,823 (99.876020%)	58,400 (0.123980%)
6.	To consider and approve the use of proceeds from the RMB Share Issue (including but not limited to the particulars as set out in the section headed "Resolution on the use of proceeds from the RMB Share Issue" in the Circular).	46,784,003 (99.320188%)	320,220 (0.679812%)
7.	To consider and approve the remedial measures for the dilution of immediate returns after the RMB Share Issue and commitments of relevant responsible entities in the form as set forth in Appendix III to the Circular.	46,784,003 (99.320188%)	320,220 (0.679812%)
8.	To consider and approve the undertakings and the corresponding binding measures in connection with the RMB Share Issue in the form as set forth in Appendix IV to the Circular.	46,784,003 (99.320188%)	320,220 (0.679812%)
9.	To consider and approve the adoption of Rules of Procedures for Shareholders' General Meetings in the form as set forth in Appendix V to the Circular which will become effective on the date of the listing of the RMB Shares on the Sci-Tech Board.	47,104,223 (100.000000%)	0 (0.000000%)
10.	To consider and approve the adoption of Rules of Procedures for Board Meetings in the form as set forth in Appendix VI to the Circular which will become effective on the date of the listing of the RMB Shares on the Sci-Tech Board.	47,104,223 (100.000000%)	0 (0.000000%)
11.	To authorise the Directors and senior management of the Company to take all actions necessary and to sign all necessary documents in connection with or to give effect to the ordinary resolutions above.	46,795,055 (99.343651%)	309,168 (0.656349%)

	SPECIAL RESOLUTION	Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
12.	To consider and approve the amendments to the Articles of Association as set forth in Appendix VII to the Circular and the adoption of the amended and restated Articles of Association with effect from the date of listing of the RMB Shares on the Sci-Tech Board.	45,447,410 (96.482666%)	1,656,813 (3.517334%)

As more than 50% of the votes held by Shareholders present at the EGM in person or by proxy were cast in favour of resolutions no. 1 to no. 11, such resolutions were duly passed as ordinary resolutions of the Company. As more than three-fourths of the votes held by Shareholders present at the EGM in person or by proxy were cast in favour of resolution no. 12, such a resolution was duly passed as a special resolution of the Company.

For details of the above resolutions, Shareholders may refer to the Notice and the Circular.

As at the date of the EGM, the total number of issued Shares of the Company was 90,419,414 Shares which represented the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the EGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM.

The Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

All Directors attended the EGM in person or by electronic means.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, April 29, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.